Instil Bio stock rises after positive data for cancer therapy in China

Published 31/07/2025, 14:26
© Reuters.

Investing.com -- Instil Bio Inc (NASDAQ:TIL) stock jumped 5.5% in premarket trading following preliminary data from a Phase 2 study of its cancer therapy in China.

The clinical-stage cell therapy company reported that ImmuneOnco Biopharmaceuticals announced positive early results for IMM2510/AXN-2510 in combination with chemotherapy for front-line patients with advanced non-small cell lung cancer (NSCLC). The study showed partial responses in 62% of efficacy evaluable patients, with particularly strong results in squamous NSCLC patients (80% response rate) compared to non-squamous NSCLC patients (46%).

The therapy demonstrated a favorable safety profile with no dose-limiting toxicities observed in the 33 safety evaluable patients. There were no treatment-related adverse events leading to dose reduction or death, and only one case led to drug discontinuation. The most common serious side effects were hematologic, while adverse events typically associated with VEGF inhibition were uncommon and generally low-grade.

Professor Caicun Zhou, lead investigator on the study, noted that the therapy "has demonstrated early but compelling activity in front-line NSCLC patients," adding that the PD-(L)1xVEGF bispecific class has potential to become the new standard of care for front-line NSCLC.

Instil Bio CEO Bronson Crouch expressed satisfaction with the preliminary results, suggesting they indicate "potential for best-in-class efficacy in the promising PD-(L)1xVEGF bispecific antibody class." The company plans to initiate a US phase 1 clinical trial before the end of this year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.